Y-mAbs Therapeutics (NASDAQ:YMAB) Given “Outperform” Rating at Wedbush

Wedbush reaffirmed their outperform rating on shares of Y-mAbs Therapeutics (NASDAQ:YMAB) in a report published on Monday morning, RTT News reports. The brokerage currently has a $23.00 price objective on the stock.

A number of other research analysts have also recently weighed in on the company. HC Wainwright lifted their target price on Y-mAbs Therapeutics from $21.00 to $22.00 and gave the company a buy rating in a report on Monday, May 13th. Truist Financial initiated coverage on shares of Y-mAbs Therapeutics in a research report on Friday, June 28th. They set a buy rating and a $21.00 price target on the stock. Two equities research analysts have rated the stock with a sell rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of Hold and an average price target of $19.29.

Y-mAbs Therapeutics Stock Up 0.3 %

NASDAQ:YMAB opened at $9.98 on Monday. The stock has a fifty day simple moving average of $11.88 and a 200-day simple moving average of $13.73. Y-mAbs Therapeutics has a 52-week low of $4.60 and a 52-week high of $20.90. The company has a market capitalization of $437.95 million, a PE ratio of -20.31 and a beta of 0.66.

Insider Buying and Selling

In other Y-mAbs Therapeutics news, insider Thomas Gad sold 7,351 shares of the firm’s stock in a transaction dated Thursday, May 23rd. The stock was sold at an average price of $13.00, for a total transaction of $95,563.00. Following the completion of the sale, the insider now directly owns 232,681 shares in the company, valued at approximately $3,024,853. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, insider Thomas Gad sold 7,351 shares of the business’s stock in a transaction that occurred on Thursday, May 23rd. The stock was sold at an average price of $13.00, for a total value of $95,563.00. Following the completion of the sale, the insider now directly owns 232,681 shares in the company, valued at approximately $3,024,853. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Bo Kruse sold 31,371 shares of the firm’s stock in a transaction dated Friday, May 31st. The shares were sold at an average price of $12.07, for a total value of $378,647.97. Following the completion of the sale, the chief financial officer now directly owns 210,877 shares in the company, valued at $2,545,285.39. The disclosure for this sale can be found here. In the last 90 days, insiders sold 99,444 shares of company stock valued at $1,203,925. Company insiders own 21.50% of the company’s stock.

Hedge Funds Weigh In On Y-mAbs Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Dimensional Fund Advisors LP grew its position in shares of Y-mAbs Therapeutics by 15.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 484,431 shares of the company’s stock worth $5,853,000 after buying an additional 65,732 shares during the period. Los Angeles Capital Management LLC raised its holdings in Y-mAbs Therapeutics by 17.3% in the fourth quarter. Los Angeles Capital Management LLC now owns 356,530 shares of the company’s stock worth $2,432,000 after purchasing an additional 52,610 shares during the period. Bank of New York Mellon Corp boosted its position in shares of Y-mAbs Therapeutics by 8.0% during the second quarter. Bank of New York Mellon Corp now owns 120,954 shares of the company’s stock worth $1,461,000 after purchasing an additional 8,974 shares in the last quarter. Rice Hall James & Associates LLC increased its position in shares of Y-mAbs Therapeutics by 4.2% in the 2nd quarter. Rice Hall James & Associates LLC now owns 89,735 shares of the company’s stock valued at $1,084,000 after buying an additional 3,589 shares in the last quarter. Finally, Campbell & CO Investment Adviser LLC acquired a new stake in Y-mAbs Therapeutics during the 4th quarter worth approximately $562,000. Institutional investors and hedge funds own 70.85% of the company’s stock.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.